ClinicalTrials.gg
RecruitingNCT07024563Updated Jul 30, 2026

Study of Ravulizumab in Pediatric Participants With Primary IgAN

A Phase 3 interventional study of Ravulizumab in IgAN, IgAVN and Immunoglobulin A Nephropathy, sponsored by Alexion Pharmaceuticals, Inc.. Recruiting at 15 sites in 7 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies in Glomerulonephritis, IGA with a site in Spain — 9 open to participants now, 16 under way, 12 of them phase 3. Glomerulonephritis, IGA · Spain.

Planned enrollment
25th of 31
36 · median 150
Started
2025
with 3 others
Phase 3
16 of 32
5 open now
Primary completion
2028-11
later than 9 of 15 live
Registered
30th of 32
by date
Lead sponsor
4 of 32
Alexion Pharmaceuticals, Inc.

Among the 32 studies in Glomerulonephritis, IGA with a site in Spain, this one is the 25th largest by planned enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2025, is one of 16 in phase 3, reaches primary completion later than 9 of the 15 other live ones, and was the 30th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

9 of the 32 studies in Glomerulonephritis, IGA with a site in Spain are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Glomerulonephritis, IGA with a site in Spain, or all of them as a file.
02

Study summary

The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.

03

Conditions studied

  • IgAN
  • IgAVN
  • Immunoglobulin A Nephropathy
  • Immunoglobulin A Vasculitis Associated Nephritis
  • Henoch-schonlein Purpura Nephritis
  • IgA Vasculitis

Keywords

  • ravulizumab
  • IgAN
  • IgAVN
  • pediatric
  • proteinuria
  • glomerulonephropathy
  • Immunoglobulin A Nephropathy
  • Immunoglobulin A Vasculitis Associated Nephritis
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 2 to \< 18 years of age at the time of signing the or assent.
  • Stable and maximum allowed or tolerated RAASI (ACEI and/or ARB) dose for ≥ 3 months prior to Screening with no planned change during Screening through Week 106.
  • UPCR ≥ 1.0 g/g from the mean of 3 first morning voids (FMV) collected within 1 week during the Screening Period
  • Estimated ≥ 30 mL/min/1.73 m2 during Screening
  • Meningococcal infection vaccine
  • Haemophilus influenzae type b and Streptococcus pneumoniae vaccine
  • Participants who are receiving SGLT2i, DEARA (eg, sparsentan), MRA, ERA, or GLP-1 agonists must be on a stable and maximum allowed or tolerated dose for ≥ 3 months prior to Screening with no planned change in dose through Week 34.
  • Established diagnosis of primary IgAN diagnosis based on kidney within 3 years prior to Screening or during the Screening Period

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of rapidly progressive glomerulonephritis
  • Secondary forms of IgAN not in the context of primary IgAN or IgAV
  • Concomitant renal disease other than IgAN or IgAVN
  • Clinical remission of IgAN/IgAVN or clinically significant improvement in proteinuria within the last 6 months.
  • Uncontrolled diabetes mellitus with > 8.5%
  • History of kidney transplant or planned kidney transplant during the Primary Evaluation Period.
  • History of other solid organ (heart, lung, small bowel, pancreas, or liver) or bone marrow transplant
  • Splenectomy or functional asplenia
  • Participants with nephrotic syndrome receiving albumin infusions or with acute kidney injury requiring dialysis within the last 6 months prior to Screening.
  • Hemolytic uremic syndrome diagnosed any time prior to Screening.
  • Planned urological surgery expected to influence kidney function within the study time frame.
  • Congenital immunodeficiency
  • Active systemic bacterial, viral, or fungal infection within 14 days prior to enrollment
  • Received biologics for the treatment of IgAN or IgAVN within≤ 6 months prior to Screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Ravulizumab

    All participants will receive a weight-based loading dose of ravulizumab on Day 1, followed by weight-based maintenance treatment with ravulizumab on Day 15 and either once every 8 weeks (q8w) thereafter or once every 4 weeks (q4w) depending on weight.

    Drug: Ravulizumab

Interventions

  • Participants will receive Ravulizumab via intravenous (IV) infusion.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Proteinuria Based on Urine Protein to Creatinine Ratio (UPCR) at Week 34

    Time frame: Baseline, Week 34

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Ravulizumab

    Time frame: Baseline up to Week 34

  2. Trough Serum Concentration (Ctrough) of Ravulizumab

    Time frame: Baseline up to Week 34

  3. Change From Baseline in Serum Free Complement Component 5 (C5) Concentration

    Time frame: Baseline up to Week 34

  4. Change from Baseline in proteinuria based on Urine Protein to Creatinine Ratio (UPCR) at Week 10

    Time frame: Baseline, Week 10

  5. Change from Baseline in Albuminuria based on Urine Albumin to Creatinine Ratio (UACR) at Week 34

    Time frame: Baseline, Week 34

  6. Number of Participants with Partial Remission

    Time frame: Week 34

  7. Annualized Total Estimated Glomerular Filtraion Rate (eGFR) over 106 weeks

    Time frame: Baseline up to Week 106

  8. Change from Baseline in eGFR

    Time frame: Baseline, Weeks 50 and 106

  9. Number of Participants with UPCR <0.5 gram of protein per gram of creatinine

    Time frame: Week 34

  10. Number of Participants With Treatment Emergent Adverse Events, Treatment Emergent Serious Adverse Events and Adverse Events of Special Interest

    Time frame: Baseline up to Week 106

  11. Number of Participants with Antidrug Antibodies to Ravulizumab and Neutralizing Antibodies

    Time frame: Baseline up to Week 106

07

Study locations

13 of 15 sites recruiting
  • Research Site
    Palo Alto, California 94304, United States
    Not yet recruiting
  • Research Site
    Aurora, Colorado 80045, United States
    Recruiting
  • Research Site
    Beijing, 100045, China
    Recruiting
  • Research Site
    Shanghai, 201102, China
    Recruiting
  • Research Site
    Genova, 16147, Italy
    Recruiting
  • Research Site
    Roma, 00165, Italy
    Recruiting
  • Research Site
    Torino, 10126, Italy
    Recruiting
  • Research Site
    Wakayama, 641-8510, Japan
    Recruiting
  • Research Site
    Seoul, 03080, South Korea
    Recruiting
  • Research Site
    Almería, 04009, Spain
    Not yet recruiting
  • Research Site
    Barcelona, 08035, Spain
    Recruiting
  • Research Site
    Barcelona, 8950, Spain
    Recruiting
  • Research Site
    Seville, 41013, Spain
    Recruiting
  • Research Site
    Taipei, 10002, Taiwan
    Recruiting
  • Research Site
    Taoyuan, 333, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Nov 2028, 41 months after the start.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's planned 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 17, 2025
StartActual
Jun 14, 2025
Primary completionEst.
Nov 29, 2028
CompletionEst.
Apr 19, 2030
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07024563
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Jun 14, 2025
Primary completion
Nov 29, 2028 (estimated)
Completion
Apr 19, 2030 (estimated)
Last update
Jul 30, 2026

Study contacts

Alexion Pharmaceuticals, Inc. (Sponsor)
Contact
clinicaltrials@alexion.com
1-855-752-2356

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion